Long-Term Safety of Baricitinib for RA
Upadacitinib Safety Similar to Other Jakinibs for RA
1 Step Closer: Study Examines Factors That Lead to RA in Hope of Developing Prevention Strategies
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
For RA Patients, Functional Disability May Precede Diagnosis
Biologics May Prevent Cardiovascular Events in RA Patients
ABX464 in Phase 2a Trials for RA
Seronegative RA May Be on the Rise
- 1
- 2
- 3
- …
- 24
- Next Page »